ArticleMSMR2026
Routine screening for antibodies to human immunodeficiency virus in the U.S. Armed Forces, active and reserve components, January 2020-June 2025.
Article in MSMR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report provides an update, through June 2025, of routine screening results for antibodies to the human immunodeficiency virus (HIV) among members of the U.S. military. The HIV-antibody seropositivity rates for active component service members from 2024 through mid-year 2025 were highest for the Navy (0.23 per 1,000 tested) and Marine Corps (0.22 per 1,000 tested), followed by the Army (0.17 per 1,000 tested), and lowest for the Air Force (0.13 per 1,000 tested) and Coast Guard (0.11 per 1,000 tested). Mid-year HIV seropositivity rates, in comparison to 2024, increased for active component service members of the Army but decreased or remained stable for all other services, as of June 2025. From January 2020 through June 2025, approximately 7 million U.S. military service members among the active component, reserve component, National Guard) were tested for antibodies to HIV, and 1,463 were identified as HIV-antibody-positive (seropositivity 0.21 per 1,000 tested). Of the 1,463 new infections identified during this period, only 40 (2.7%) were among female service members. The HIV-antibody screening program remains an important element of U.S. force health protection, particularly for men under age 35 years, for all branches of service and service components. The measurement of military retention for HIV-positive service members reflects changes in U.S. Department of Defense policies that allow asymptomatic individuals with undetectable viral loads to serve without restrictions.
Indexed as
Identifiers
41615905PMC12945326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.